How is tucatinib administered?

Tucatinib is an oral HER2 tyrosine kinase inhibitor, mainly used to treat adult patients with HER2-positive breast cancer who have metastasized (such as brain metastases) or who are unable to undergo mastectomy.

The recommended starting dose of tucatinib is300 mg twice daily. This dose was established when used in combination with trastuzumab and capecitabine. Patients need to take medication under the guidance of a doctor and adjust the dosage according to the doctor's instructions.

Tucatinib is an oral medication and patients need to swallow the tablet whole and avoid chewing, crushing or splitting it. Patients should take tucatinib at the same time each day, approximately 12 hours apart. For example, take it once at 8 o'clock in the morning and once at 8 o'clock in the evening. This maintains a stable concentration of the drug in the body.

Tucatinib can be taken with or on an empty stomach. However, it is recommended that patients take it under the same conditions every day (such as on an empty stomach or with food) to ensure consistent absorption of the drug.

During the course of medication, if the patient experiences adverse reactions or changes in condition, the doctor may adjust the dosage of tucatinib as necessary. Patients should strictly follow the doctor's instructions and do not change the dosage or stop taking the medicine on their own.

The use of tucatinib in combination with capecitabine and trastuzumab is not recommended in patients with severe renal insufficiency (creatinine clearance<30 mL/min). No dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance 30-89 mL/min). When using tucatinib in special populations, special attention needs to be paid to drug risk assessment.

Tucatinib may cause serious side effects, such as diarrhea and liver disease. Patients should monitor their symptoms closely and report any discomfort to their doctor promptly. The doctor will handle and adjust the medication plan accordingly according to the patient's specific situation.

Tucatinib showed increased antitumor activity when combined with trastuzumab and capecitabine. However, interactions with other drugs have not been established. Therefore, while using tucatinib, patients should inform their doctors about all the drugs they are taking (including prescription drugs, over-the-counter drugs, health products, etc.) to avoid the risk of potential drug interactions.

References:

https://www.drugs.com/dosage/tucatinib.html